Zafgen, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic diseases. The company is headquartered in Boston, Massachusetts, USA. Their primary focus is on addressing unmet medical needs in obesity and related metabolic disorders through the development of selective agonists targeting the melanocortin-4 receptor (MC4R). Zafgen's lead product candidate, belantamab mafodotin-blmf, has been discontinued.

Their approach centers on understanding the complex interplay of hormones and signaling pathways that regulate energy balance and metabolism. This understanding underpins their development of therapies aiming to correct imbalances that contribute to conditions like obesity and related metabolic disorders. While they have had setbacks with previous drug candidates, their research and development efforts continue to be focused on identifying and advancing novel therapies targeting key biological pathways relevant to metabolic disease. Further specifics on current research and pipeline candidates would require accessing current information directly from their official website or other public disclosures. Their operations involve the entire biopharmaceutical process, from research and discovery to pre-clinical and clinical development, and eventually, commercialization. The company's success hinges on the continued development and regulatory approval of their pipeline candidates, ultimately aiming to improve the lives of patients with metabolic disorders.